Cancer-reactive T cells from Peripheral Blood

Adoptive cell therapy (ACT) using genetically engineered T-cell receptors (TCRs) is a promising cancer treatment. These TCRs target genetic mutations unique to patients and play an important role in tumor regression. However, mutation-reactive T-cells and their TCRs can be difficult to identify and isolate from patients. Therefore, we need more efficient methods of isolating mutation-reactive T-cells for use with ACT.Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient ’s peripheral blood lymphocytes (PBL). The researchers found that mutation-reactive T-cells in the PBL are enriched with various markers including CD8, programmed cell death 1 (PD-1), and T cell immunoglobulin and mucin domain 3 (TIM-3). These T-cells and their TCRs can be isolated from the blood and then administered to patients as a cancer therapeutic.IC: NCINIH Ref. No.: E-149-2015/0Advantages: Applicable to patients without tumors available for resectionMore cost effective compared to surgical resection for procurement of tumor infiltrating lymphocytesApplications: Personalized immunotherapy to treat cancer patientsResearch tool to identify T-cells and TCRs targeting patient-specific mutationsProvider Technology ID: 3236Updated On: Dec 18, 2017Provider Classifications: Date Published: Monday, December 18, 2017Publications: Patent Application: 62/155,830PCT/US2016/03013715/567...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research